scholarly journals Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: A Descriptive Cross-Sectional Study in Tertiary Care Hospital

Cureus ◽  
2020 ◽  
Author(s):  
Abubakar Tauseef ◽  
Maryam Zafar ◽  
Behzad Rashid ◽  
Joseph Thirumalareddy ◽  
Victor Chalfant ◽  
...  
2021 ◽  
Vol 59 (244) ◽  
pp. 1225-1228
Author(s):  
Abashesh Bhandari ◽  
Ashlesha Chaudhary

Introduction: Hyponatremia is a frequent problem in chronic liver disease. To the best of our knowledge, no study of hyponatremia in chronic liver disease has been conducted in our setting. The aim of this study is to study the prevalence of hyponatremia in patients with chronic liver disease attending the outpatient department of a tertiary care hospital. Methods: This descriptive cross-sectional study was conducted in 114 patients with chronic liver disease attending the out-patient department of a tertiary care hospital in Kathmandu, Nepal between November 2020 and July 2021. Ethical approval was taken from the Institutional Review Committee of Nepal Medical College and Teaching Hospital (Reference number: 028-077/078). Convenience sampling was done. The collected data was entered and analyzed in Microsoft Excel. Calculation of point estimate at 95% confidence interval was done along with frequency and proportion for binary data. Results: Among 114 patients with chronic liver disease studied, 47 (41.22%) (32.18-50.25 at 95% Confidence Interval) patients had hyponatremia (≤130mmol/L) with mean age of 53.44±7.57 years. Thirty (63.8%) patients out of these were males and 17 (36.2%) patients were females. Conclusions: The prevalence of hyponatremia among patients with chronic liver disease was found to be higher when compared to other similar studies.


Author(s):  
Hashik P. Muhammed ◽  
Kezhakkut Jayaraj

Background: Many previous studies concluded variation in the lipid parameters such as total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) with severity of liver disease. Hence, this study was conducted to find out the correlation of lipid profile in patients with severe liver disease.Methods: A cross sectional study which included 170 patients admitted with chronic liver disease. Severity of liver disease according to Child Pugh Turcotte Score. The patients were subjected to routine investigation and fasting lipid profile test. Correlation was studied using the Pearson correlation coefficient and the comparison of lipid parameters was also done.Results: Total of 170 consecutive chronic liver disease patients were analysed over a period of one year. Majority of the patients were of the age 51 to 60 years (39.8%). Among the total, 24 patients were in Child Pugh Turcotte Score class A, 47 patients were in class B and 52 were patients in class C. We could observe a significant (p<0.001) negative correlation of all the lipid profile parameters with the severity of liver disease.Conclusions: Serum TC, LDL TG and HDL were decreased in patients with cirrhosis and they are inversely correlated to severity of disease.


2021 ◽  
Vol 15 (10) ◽  
pp. 2831-2832
Author(s):  
Ambreen Asif ◽  
Kashif Aziz Ahmad ◽  
Sohaib Akbar ◽  
Talha Munir

Objective: frequency of dyslipidemia in obese subjects Methodology: In this was a cross sectional study, we included a total of 100 cases, between 30 and 70 years of age of either gender having body mass index >30 whereas we excluded all those cases who were already taking treatment of dyslipidemia. A fasting blood sample was followed for lipid profile from the hospital lab and results were followed for presence/absence of dyslipidemia. Results: In this trial, mean age was 44.57+8.52 years. Mean lipid profile was recorded as 210.17+36.73 total cholesterol, 178.83+12.10 triglycerides, 133.55+9.74 LDL and 34.42+6.58 HDL. Mean Body mass index was calculated as 34.11+7.25. Frequency of dyslipidemia in obese subjects was recorded as 51%(n=51) Conclusion: We concluded that frequency of dyslipidemia is higher in obese subjects coming to a tertiary care hospital Lahore. So, it is recommended that every patient who present with obesity, should be sort out for dyslipidemia. However, it is also required that every setup should have their surveillance in order to know the frequency of the problem Keywords: Obese, dyslipidemia, frequency


2018 ◽  
Vol 8 (3) ◽  
pp. 170-173
Author(s):  
Zulfiqar Ali Shaikh ◽  
Javeria Shamim ◽  
Kelash Nankani

Background: Hepatitis C is among one of the major global health issues; which may cause chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently requiring liver transplant. For HCV, standard treatment is a combination therapy of ribavirin and interferon for six months. Ribavirin fostered hemolysis is a major treatment-associated adverse effect. Our study aimed to assess ribavirin induced anemia among Hepatitis C patients visiting Civil Hospital, Karachi. Methods: A hospital-based cross-sectional study which included 106 Hepatitis C patients, of 15-60 years' age, visiting CHK, a public sector tertiary care hospital, from October 2017 to January 2018 by using non-probability convenient sampling technique. Results: Total 106 patients participated, 53 (50.0%) were males and 53 (50.0%) were females. Mean (±SD) age was 37.05 (±10.793). Mean (±SD) duration of ribavirin use was 3.03 (±1.523) months. Around 16.0% had ribavirin dose reduction. All of them experienced weakness, fatigue and light-headedness, 59.4% developed microcytic hypochromic anemia, 23.6% had severe anemia. Mean (±SD) hemoglobin level before the onset of treatment was 12.78 (±1.555). Mean hemoglobin level during treatment was 10.72g/dL. Mean reduction in hemoglobin levels was 2.07g/dL. The reduction in hemoglobin levels and the duration of therapy were correlated (p-value <0.05). The severity of anemia was related to age of the patients (p-value <0.05) but not with gender and RBC morphology. Conclusion: Ribavirin induces anemia. The duration of ribavirin therapy and initial hemoglobin levels were related to the severity of anemia, significant enough to cause dose modification and subsequently suboptimal levels affecting efficacy. In return hemoglobin reduction, dose modification and age of the patient were also related.


Vacunas ◽  
2020 ◽  
Vol 21 (2) ◽  
pp. 95-104 ◽  
Author(s):  
Y.M. AlGoraini ◽  
N.N. AlDujayn ◽  
M.A. AlRasheed ◽  
Y.E. Bashawri ◽  
S.S. Alsubaie ◽  
...  

Author(s):  
Nandini Chatterjee ◽  
Supratick Chakraborty ◽  
Mainak Mukhopadhyay ◽  
Sinjon Ghosh ◽  
Bikramjit Barkandaj ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document